<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="224">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01251809</url>
  </required_header>
  <id_info>
    <org_study_id>MC-PEGASP.1/adults</org_study_id>
    <nct_id>NCT01251809</nct_id>
  </id_info>
  <brief_title>Trial of Oncaspar® and Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukaemia</brief_title>
  <official_title>A Randomized, Multi-centre, Parallel-group, Open Label, Oncaspar® Controlled Dose Ranging Trial of Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>medac GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an assessment of efficacy and safety of three different doses of pegylated
      recombinant asparaginase (PEG-rASNase) in comparison to Oncaspar® during treatment of adults
      with de novo acute lymphoblastic leukaemia (ALL). This study will provide first data for
      determining specific asparaginase doses to yield various durations of L-asparagine (ASN)
      depletion which are required within different treatment phases of ALL therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>To compare the rate of patients with asparagine depletion 3 weeks after infusion of PEG-rASNase or Oncaspar® in the induction phase.</measure>
    <time_frame>3 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the rate of patients with asparagine depletion 3 weeks after infusion of PEG-rASNase or Oncaspar® in the induction phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparing of treatment arms</measure>
    <time_frame>62 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>-the rate of patients with asparagine depletion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing of treatment arms</measure>
    <time_frame>62 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>the rate of patients with L-asparaginase (ASNase) activity levels in serum &gt; 100 U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing of treatment arms</measure>
    <time_frame>62 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>the duration of ASNase activity levels in serum &gt; 100 U/L and its variability pharmacokinetic parameters Cmax, t½, CLtotal, Kel, AUC0-t and AUC0-∞</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing of treatment arms</measure>
    <time_frame>62 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>the time profiles of ASNase activity and amino acid levels Asparagine (ASN), Aspartic acid (ASP), Glutamine (GLN) and Glutamic acid (GLU) in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing of treatment arms</measure>
    <time_frame>62 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the incidence of increased bilirubin grade III/IV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing of treatment arms</measure>
    <time_frame>62 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the incidence of all other adverse events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Acute Lymphoblastic Leukaemia</condition>
  <arm_group>
    <arm_group_label>PEG-rASNase 500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 U/m2 BSA at day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-rASNase 1000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 U/m2 BSA at day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-rASNase 1500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1500 U/m2 at day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oncaspar</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2000 U/m2 at day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oncaspar</intervention_name>
    <description>2000 U/m2 BSA, single infusion</description>
    <arm_group_label>Oncaspar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-rASNase</intervention_name>
    <description>500, 1000 or 1500 U/m2 BSA single infusion</description>
    <arm_group_label>PEG-rASNase 500</arm_group_label>
    <arm_group_label>PEG-rASNase 1000</arm_group_label>
    <arm_group_label>PEG-rASNase 1500</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated acute lymphoblastic leukaemia (pro-B, common, pre-B, early T,
             thymic T, mature T)

          -  Age 18 years - 55 years

          -  Treatment according to German Multicenter Trials for adult Acute Lymphoblastic
             Leukaemia (GMALL) 07/2003 protocol or subsequent GMALL protocols for patients with de
             novo ALL

          -  Written informed consent

          -  Women of child-bearing potential or partner of men with child-bearing potential must
             use a highly effective method of contraception

          -  Negative pregnancy test for women of child-bearing potential

        Exclusion Criteria:

          -  Patients with Philadelphia chromosome (BCR-ABL) positive ALL

          -  Severe comorbidity or leukaemia-associated complications

          -  Known hypersensitivity to asparaginase

          -  History of severe pancreatitis

          -  History of thrombosis or pulmonary embolism

          -  Pre-existing clinically relevant coagulopathy

          -  Liver dysfunction (e.g. acute or current hepatitis, alcohol or drug abuse) or history
             of clinically relevant liver disease

          -  Bilirubin &gt; 1.5 x Upper Limit Norm (ULN)

          -  Other current malignancies

          -  Severe psychiatric illness or other circumstances which may compromise the
             cooperation of the patient or the ability to give informed consent

          -  Body mass index &gt; 30 kg/m²

          -  Known pregnancy, breast feeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H. A. Horst, Prof.</last_name>
      <phone>0049 (0) 431 1697</phone>
      <phone_ext>1272</phone_ext>
    </contact>
    <investigator>
      <last_name>H. A. Horst, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <lastchanged_date>December 21, 2010</lastchanged_date>
  <firstreceived_date>November 26, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Elena Osswald, MD</name_title>
    <organization>medac GmbH</organization>
  </responsible_party>
  <keyword>Asparaginase</keyword>
  <keyword>ALL</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>
</clinical_study>
